# A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT07693738** · PHASE1 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- AD

## Interventions

- **DRUG:** SSGJ-716
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07693738
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2027-08-29
- **Final completion:** 2028-01-29
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693738, "A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*